ArticleArchives of medical science : AMS2022
Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and possibilities in healthcare.
Article in Archives of medical science : AMS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 17 citations in OpenAlex.
- The causal effects of placental weight on atherosclerotic cardiovascular disease: a Mendelian randomization and mediation analysis.Archives of medical science : AMS · 2025Article
- Mendelian randomization studies of diagnostic value of standard biochemistry serum enzymes portfolio in cardiovascular diseases.Archives of medical science : AMS · 2025Article
- RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.Molecular therapy. Nucleic acids · 2024Review
- Dyslipidaemia management in pregnant patients: a 2024 update.European heart journal open · 2024Review
- Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology.Archives of medical science : AMS · 2024Article
- Summary of 2023 and the biggest challenges for the "Archives of Medical Science" on its 20Archives of medical science : AMS · 2024Article
- New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets.International journal of molecular sciences · 2023Review
- Lipoprotein(a): the enemy that we still don't know how to defeat.European heart journal open · 2023Article
- Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).Pharmaceuticals (Basel, Switzerland) · 2023Review
- Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.International journal of molecular sciences · 2023Review
- 2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?Archives of medical science : AMS · 2023Article
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study.Frontiers in cardiovascular medicine · 2023Article
- Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia.Journal of clinical medicine · 2022Review
- Comprehensive Care after Myocardial Infarction (CCMI): Long-Term Investment in the Health of Polish Citizens.International journal of environmental research and public health · 2022Review
- 2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.Archives of medical science : AMS · 2022Article
- Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis.Archives of medical science : AMS · 2022Article
- Alcohol and health. Is regular drinking of small doses of alcohol really good for your health?Archives of medical sciences. Atherosclerotic diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.